DAG Lipase β Antibody [K18L4]

Catalog No.: F6053

    Application: Reactivity:
    • Lane 1: MCF7, Lane 2: THP-1, Lane 3: RAW, Lane 4: Neuro-2a
    1/

    当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    1:50
    1:50
    Application
    WB, IP
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human, Mouse, Rat
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW
    70 kDa

    Datasheet & SDS

    生物学的記述

    Specificity
    DAG Lipase β Antibody [K18L4] detects endogenous levels of total DAG Lipase β protein.
    Clone
    K18L4
    Synonym(s)
    Sn-1-specific diacylglycerol lipase beta; DAGLB
    Background
    Diacylglycerol lipase β (DAGLβ) is one of two closely related serine hydrolase isozymes that hydrolyze diacylglycerol (DAG) at the sn‑1 position to generate 2‑arachidonoylglycerol (2‑AG), a major endocannabinoid ligand for cannabinoid CB1 and CB2 receptors. DAGLβ is a membrane‑associated protein with multiple transmembrane domains and a large C‑terminal cytoplasmic region containing the catalytic triad, and this architecture supports its localization to intracellular membranes and lipid‑rich compartments where it accesses DAG pools generated downstream of phospholipase‑coupled receptor signaling. DAGLβ is preferentially expressed in cells of the mononuclear phagocytic system and other immune‑related cell types, and it converts arachidonic‑acid‑containing DAG into 2‑AG and free arachidonic acid, thereby feeding both endocannabinoid signaling and downstream eicosanoid production that modulate inflammatory and nociceptive pathways. DAGLβ‑derived 2‑AG and arachidonic acid contribute to macrophage‑driven inflammation, LPS‑induced allodynia, and pro‑tumorigenic signaling in cancers such as intrahepatic cholangiocarcinoma, where upregulation of DAGLβ is associated with metastasis and correlates with AP‑1‑driven transcriptional circuits and inflammatory feed‑forward loops, and pharmacological or genetic inhibition of DAGLβ reduces local 2‑AG and eicosanoid levels, dampens pro‑inflammatory cytokine output, and reverses inflammatory and neuropathic pain phenotypes in model systems. DAGLα is the dominant isoform for synaptic 2‑AG, but DAGLβ also contributes to neuronal and microglial 2‑AG pools in cell‑type‑specific settings, and its activity is tightly regulated by Ca²⁺‑dependent signaling, receptor‑coupled DAG generation, and post‑translational modifications.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください